Agile Therapeutics to Host First Analyst Day on October 10, 2017 Print
By GLOBE NEWSWIRE   
Monday, 02 October 2017 01:30

PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE)

PRINCETON, N.J., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Agile Therapeutics, Inc., (NASDAQ:AGRX), a women's healthcare company, today announced that the Company will host its first Analyst Day on Tuesday, October 10, 2017 in New York City.

Members of Agile’s executive team will review clinical data and discuss the commercialization plan for Twirla®, the company's lead investigational once weekly low-dose prescription contraceptive patch.  Management will be joined by leading external experts who will provide clinical perspectives on Twirla, as well as regulatory and market access insights into today’s contraceptive marketplace.

To access the live webcast, visit the Investor Relations section of Agile Therapeutics website at www.agiletherapeutics.com. A replay will be available on the company’s website.

Event Details 
 
Date: Tuesday, October 10, 2017
Time: 11:00 a.m. – 1:30 p.m. ET 
Location: New York City


Speakers will include:
  
Alfred Altomari Chairman and CEO, Agile Therapeutics
 
Elizabeth Garner, M.D., MPH Senior Vice President, Chief Medical Officer, Agile Therapeutics
 
Renee Selman Chief Commercial Officer, Agile Therapeutics
 
Robin Kroll, M.D., FACOG Director, Seattle Women’s: Health, Research, Gynecology; 
 SECURE Trial Investigator 
 
David J. Portman, M.D., FACOG Director Emeritus, Columbus Center for Women’s Health 
 Research; CEO and Chief Medical Officer, Sermonix 
 Pharmaceuticals
 
Minnie Baylor-Henry, J.D., R.PhExecutive Partner, YourEncore; Former Director, Division of 
 Drug Marketing, Advertising and Communications (DDMAC), 
 Food and Drug Administration; Former Worldwide Vice 
 President, Regulatory Affairs, Johnson & Johnson
 
Adaeze Enekwechi, PhD, MPP VP, McDermottPlus Consulting in Washington,D.C.; Former 
 Associate Director for Health Programs, White House Office of 
 Management and Budget under President Obama

Analysts and

institutional investors seeking more information about this event should contact Matt Ventimigila by phone or email: MVentimiglia@lazarpartners.com, or 212-599-1265.

About Agile Therapeutics
Agile Therapeutics is a forward-thinking women's healthcare company dedicated to fulfilling the unmet health needs of today's women. Our product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Our lead product candidate, Twirla®, (ethinyl estradiol and

Error. Page cannot be displayed. Please contact your service provider for more details. (8)

levonorgestrel transdermal system), also known as AG200-15, is a once-weekly prescription contraceptive patch that recently completed Phase 3 trials. Twirla is based on our proprietary transdermal patch technology, called Skinfusion®, which is designed to provide advantages over currently available patches and
is intended to optimize patch adhesion and patient wearability. For more information, please visit the company website at www.agiletherapeutics.com.  The company may occasionally disseminate material, nonpublic information on the company website.

Follow Agile on Twitter: @agilether. The company may occasionally disseminate material, nonpublic information on the company website.

About Twirla®
Twirla (ethinyl estradiol and levonorgestrel transdermal system) or AG200-15 is an investigational once-weekly prescription contraceptive patch. AG200-15 is a combined hormonal contraceptive (CHC) patch that contains the active ingredients ethinyl estradiol (EE), a synthetic estrogen, and levonorgestrel (LNG), a type of progestin, a synthetic steroid hormone. Twirla is designed to be applied once weekly for three weeks, followed by a week without a patch.

Contact:
Mary Coleman 
Agile Therapeutics, Inc.
609-356-1921

Primary Logo




BiomedReports is not paid or compensated by newswires to disseminate or report news and developments about publicly traded companies, but may from time to time receive compensation for advertising, data, analytics and investor relation services from various entities and firms. Full disclosures should be read in the 'About Us Section'.

Add this page to your favorite Social Bookmarking websites
Digg! Reddit! Del.icio.us! Mixx! Google! Live! Facebook! Technorati! StumbleUpon! MySpace! Yahoo!
  BMR:1